Soluble expression, purification and characterization of the full length IS2 Transposase von Lewis, Leslie A, Astatke, Mekbib, Umekubo, Peter T, Alvi, Shaheen, Saby, Robert, Afrose, Jehan

Volltext

Protein-DNA interactions define the mechanistic aspects of circle formation and insertion reactions in IS2 transposition von Lewis, Leslie A, Astatke, Mekbib, Umekubo, Peter T, Alvi, Shaheen, Saby, Robert, Afrose, Jehan, Oliveira, Pedro H, Monteiro, Gabriel A, Prazeres, Duarte Mf

Volltext

The Left End of IS2: a Compromise between Transpositional Activity and an Essential Promoter Function That Regulates the Transposition Pathway von LEWIS, Leslie A, CYLIN, Edruge, HO KYUNG LEE, SABY, Robert, WONG, Wilson, GRINDLEY, Nigel D. F

Volltext

Soluble expression, purification and characterization of the full length IS 2 Transposase von Lewis, Leslie A, Astatke, Mekbib, Umekubo, Peter T, Alvi, Shaheen, Saby, Robert, Afrose, Jehan

Volltext

Protein-DNA interactions define the mechanistic aspects of circle formation and insertion reactions in IS 2 transposition von Lewis, Leslie A, Astatke, Mekbib, Umekubo, Peter T, Alvi, Shaheen, Saby, Robert, Afrose, Jehan, Oliveira, Pedro H, Monteiro, Gabriel A, Prazeres, Duarte MF

Volltext

The Left End of IS 2 : a Compromise between Transpositional Activity and an Essential Promoter Function That Regulates the Transposition Pathway von Lewis, Leslie A., Cylin, Edruge, Lee, Ho Kyung, Saby, Robert, Wong, Wilson, Grindley, Nigel D. F.

Volltext

The basis of asymmetry in IS2 transposition von Lewis, Leslie A., Gadura, Nidhi, Greene, Marsha, Saby, Robert, Grindley, Nigel D. F.

Volltext

The basis of asymmetry in IS 2 transposition von Lewis, Leslie A., Gadura, Nidhi, Greene, Marsha, Saby, Robert, Grindley, Nigel D. F.

Volltext

Will European soil-monitoring networks be able to detect changes in topsoil organic carbon content von SABY, NICOLAS P.A, BELLAMY, PATRICIA H, MORVAN, XAVIER, ARROUAYS, DOMINIQUE, JONES, ROBERT J.A, VERHEIJEN, FRANK G.A, KIBBLEWHITE, MARK G, VERDOODT, ANN, ÜVEGES, JUDIT BERÉNYI, FREUDENSCHUß, ALEXANDRA, SIMOTA, CATALIN

Volltext

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial von Cella, David, Grünwald, Viktor, Escudier, Bernard, Hammers, Hans J, George, Saby, Nathan, Paul, Grimm, Marc-Oliver, Rini, Brian I, Doan, Justin, Ivanescu, Cristina, Paty, Jean, Mekan, Sabeen, Motzer, Robert J

Volltext

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma von Motzer, Robert J., McDermott, David F., Escudier, Bernard, Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Barthélémy, Philippe, Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Gurney, Howard, Kollmannsberger, Christian K., Grimm, Marc‐Oliver, Barrios, Carlos, Tomita, Yoshihiko, Castellano, Daniel, Grünwald, Viktor, Rini, Brian I., McHenry, M. Brent, Lee, Chung‐Wei, McCarthy, Jennifer, Ejzykowicz, Flavia, Tannir, Nizar M.

Volltext

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlle... von Motzer, Robert J, Rini, Brian I, McDermott, David F, Arén Frontera, Osvaldo, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, Tannir, Nizar M

Volltext

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial von Motzer, Robert J, Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C, Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel

Volltext

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial... von Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

Volltext

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial von Motzer, Robert J, Rini, Brian I, McDermott, David F, Redman, Bruce G, Kuzel, Timothy M, Harrison, Michael R, Vaishampayan, Ulka N, Drabkin, Harry A, George, Saby, Logan, Theodore F, Margolin, Kim A, Plimack, Elizabeth R, Lambert, Alexandre M, Waxman, Ian M, Hammers, Hans J

Volltext

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial von Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J

Volltext

Spatial variability of soil microbial functioning in a tropical rainforest of French Guiana using nested sampling von Fromin, Nathalie, Saby, Nicolas P.A., Lensi, Robert, Brunet, Didier, Porte, Benjamin, Domenach, Anne-Marie, Roggy, Jean-Christophe

Volltext

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma von Rini, Brian I, Signoretti, Sabina, Choueiri, Toni K, McDermott, David F, Motzer, Robert J, George, Saby, Powles, Thomas, Donskov, Frede, Tykodi, Scott S, Pal, Sumanta K, Gupta, Saurabh, Lee, Chung-Wei, Jiang, Ruiyun, Tannir, Nizar M

Volltext